<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167451</url>
  </required_header>
  <id_info>
    <org_study_id>2014-1221</org_study_id>
    <nct_id>NCT02167451</nct_id>
  </id_info>
  <brief_title>Maraviroc as GVHD Prophylaxis in Transplant Recipients</brief_title>
  <official_title>Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine if the addition of Maraviroc to a standard transplant regimen
      will reduce the incidence of graft versus host disease in children and young adults after a
      stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first stage, drug levels will be obtained to establish appropriate dosing. In the
      second stage of the study the investigators will study the effects of using Maraviroc in
      these patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>Up to day +100</time_frame>
    <description>The ability to administer twice daily oral maraviroc in children and adults undergoing stem cell transplant in addition to routine standard graft versus host disease prophylaxis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GVHD Incidence</measure>
    <time_frame>By day +100</time_frame>
    <description>Clinical data to be collected and reported include the onset of GVHD, grade, organ involved, and treatments used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Concentration-Time Curve (AUC) of Maraviroc</measure>
    <time_frame>Day 0 and day +10</time_frame>
    <description>pK target &gt;100ng/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>By day +100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure</measure>
    <time_frame>By day +100</time_frame>
    <description>Failure to engraft and loss of graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Disease Relapse</measure>
    <time_frame>By day +100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>Up to day +100</time_frame>
    <description>Incidence of toxicities either due to drug or transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious Complications</measure>
    <time_frame>Up to day +100</time_frame>
    <description>Infections complications which include asymptomatic viremias for EBV, Adenovirus, CMV, and/or viral disease, bacterial and fungal infections as documented by blood cultures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Neutrophil and Platelet Engraftment</measure>
    <time_frame>Up to day +100</time_frame>
    <description>Neutrophil engraftment is defined as the first of three consecutive measurements of ANC&gt;500mcL over 3 or more days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Diagnoses That Require Stem Cell Transplant</condition>
  <condition>Graft Versus Host Disease (GVHD)</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 5 years and &lt;/= 40 years

          -  All diagnoses

          -  Peripheral blood stem cells, marrow or cord blood

          -  All conditioning regimens

          -  Patient must be planned to receive a calcineurin inhibitor (cyclosporine or
             tacrolimus) together with steroid, methotrexate or mycophenolate mofetil as GVHD
             prophylaxis.

        Exclusion Criteria:

          -  Documented anaphylaxis to Maraviroc

          -  Ex vivo T-cell (type of white blood cell) depleted grafts

          -  Abnormal Alanine Aminotransferase (ALT) (&gt;/=10X ULN) on day -3. (Assessed at study
             enrollment and confirmed again prior to the first dose of maraviroc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pooja Khandelwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Jordan</last_name>
    <phone>513-636-4379</phone>
    <email>Melanie.Jordan@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Edwards, BSN, RN</last_name>
    <phone>513-636-9292</phone>
    <email>StephanieL.Edwards@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Mitchell</last_name>
      <phone>513-636-4174</phone>
      <email>Sharon.Mitchell@cchmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2014</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stem cell transplant</keyword>
  <keyword>GVHD prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

